Senolytics

Small molecule senolytics trigger apoptosis in senescent cells specifically. Senomorphics modify SASP secretion without killing senescent cells. Targeted delivery systems direct senolytics to specific tissues. Biomarkers of senescent cell burden measure treatment effect. Combination approaches target multiple senescence pathways.

Clinical trials test senolytics for osteoarthritis, diabetic kidney disease, and pulmonary fibrosis. Senescence biomarkers assess biological age and treatment response. Consumer supplements (fisetin, quercetin) are used despite limited clinical evidence. Preclinical models test senolytics across age-related conditions.

The senolytic therapeutics market is pre-commercial, with several candidates in clinical trials. If successful, the addressable market spans virtually every age-related disease.